Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

COLOMBES Cedex, France Clinical Trials

A listing of COLOMBES Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

RI is associated with poor prognosis and short median survival (32 months vs 55 months for MM patients with normal renal function). Thus, RI remains a major challenge for hematologists, including decisions on optimal anti-myeloma therapy, potential dialysis, supportive care and quality of life. The combination of a proteasome inhibitor ...

Phase N/A

2.19 miles

Learn More »

Chronic Neuropathic Pain After Lung Surgery: Prevalence and Predictive Factors

Chronic post-thoracotomy pain is the most common long-term complication that occurs after a thoracotomy with a reported incidence of up to 80%. Surgical approach as well as other factors (genetic, psychological) could have a major and independent role in the development of the post operative pain.The main objective of this ...

Phase N/A

3.83 miles

Learn More »

Prediction of Chronic Renal Disease After Acute Kidney Injury in the Intensive Care Unit

As second objectives, the study aims to: Evaluate the GFR decline in patients who had an underlying chronic kidney disease. Evaluate factors associated with a persistent decreased GFR at day-90. Characterization the clinical and biological phenotype of chronic renal disease in these patients. Evaluate treatments provided to these patients according ...

Phase N/A

6.19 miles

Learn More »

Endomysial Fibrosis Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is the most common and devastating form of muscular dystrophy, caused by an X-chromosome gene mutation resulting in the absence of the protein dystrophin. Gene therapy by exon skipping or stop codon read-through and cell therapy are at the stage of clinical assays with very promising ...

Phase N/A

6.37 miles

Learn More »

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial hypercholesterolemia (HoFH). The secondary objectives of the study are to evaluate the effect of evinacumab IV on other ...

Phase

6.37 miles

Learn More »

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast ...

Phase

7.04 miles

Learn More »

Preeclampsia Ratio (sFlt-1/PlGF)

Preeclampsia is a hypertensive disorder of pregnancy associated with placental insufficiency and is one of the major important of prematurity and maternal mortality worldwide. It complicates 2 to 7% of pregnancies. It is currently considered that preeclampsia is associated with maternal endothelial dysfunction induced by the release into the maternal ...

Phase N/A

7.07 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.

Phase

7.07 miles

Learn More »

A clinical research study called 'POINT' will evaluate if adding an oral study drug to Tecfidera® can have an effect on multiple sclerosis (MS) disease activity. In this study, patients with active relapsing MS will receive add-on therapy with ponesimod (a sphingosine 1-phosphate [S1P] receptor modulator) or placebo on top ...

Phase

7.71 miles

Learn More »